Table 1.

Cox regression analysis of treatment-free survival in the whole cohort

		Univariable		Multivariable (n = 365)
	N pts analyzed	HR (95% CI)	p-value	HR (95% CI)	p-value
male gender	442	0.97 (0.76–1.22)	0.8	−	−
age ≥ 65	441	0.97 (0.77–1.23)	0.8	−	−
Rai stage II–III–IV	434	2.60 (2.03–3.32)	<0.0001	2.59 (1.98–3.41)	<0.0001
CD49d positive (≥30%)	440	1.48 (1.13–1.92)	0.004	1.65 (1.22–2.23)	0.001
CD38 positive (≥30%)	439	1.13 (0.89–1.43)	0.3	−	−
ZAP-70 positive (≥20%)	389	1.44 (1.11–1.87)	0.005	n.i.	n.i.
IGHV unmutated	428	2.16 (1.66–2.8)	<0.0001	1.83 (1.37–2.45)	<0.0001
TP53 disrupted (del17p and/or TP53 mutated)	442	1.70 (1.24–2.32)	0.0008	1.46 (1.05–2.03)	0.024
NOTCH1 mutated	442	1.37 (1.08–1.73)	0.009	n.i.	n.i.
SF3B1 mutated	327	1.46 (0.90–2.38)	0.1	−	−
BIRC3 mutated	343	0.93 (0.65–1.34)	0.7	−	−
KRAS mutated	442	1.49 (0.96–2.30)	0.073	−	−
NRAS mutated	442	1.86 (0.99–3.50)	0.055	−	−
BRAF mutated	442	1.34 (0.75–2.40)	0.3	−	−
KRAS/NRAS mutated	442	1.54 (1.05–2.25)	0.025	1.56 (1.04–2.36)	0.033

Factors with p-value <0.05 in univariable analysis were entered in the multivariable analysis

HR hazard ratio, CI confidence interval, n.i. variables not included in the model after stepwise selection